Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study

Michael Jarratt, Terry Jones, Steven Kempers, Phoebe Rich, Katy Morton, Norifumi Nakamura, Amir Tavakkol

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tinea pedis (TP) typically is treated with topical antifungal agents. Luliconazole, a novel imidazole drug, is shown to be as or more effective in vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment durations with luliconazole cream 1% were evaluated for treatment of TP. Participants with interdigital TP were randomized (N=147) and treated with either luliconazole or its vehicle for either 2 or 4 weeks. The primary efficacy end point was the proportion of participants achieving complete clearance 2 weeks following completion of treatment. In the 2-week active treatment group, complete clearance was achieved in 26.8% (11/41) of participants versus 9.1% (2/22) in the 2-week vehicle group at 2-weeks posttreatment. In the 4-week active treatment group, 45.7% (16/35) achieved complete clearance versus 10.0% (2/20) in the 4-week vehicle group at 2-weeks posttreatment. Twenty-three adverse events (AEs) were reported; most were mild (56.5% [13/23]) to moderate (26.1% [6/23]) in severity. All reported AEs were determined to be unrelated (78.3% [18/23]) or unlikely related (21.7% [5/23]) to the study medication. The results of this study indicate that luliconazole cream 1% applied once daily for either 2 or 4 weeks is safe and effective for treatment of TP. More importantly, the antifungal effects of luliconazole persist for several weeks, resulting in increased rates of mycological cure.

Original languageEnglish (US)
Pages (from-to)203-210
Number of pages8
JournalCutis
Volume91
Issue number4
StatePublished - Aug 22 2013
Externally publishedYes

Fingerprint

Tinea Pedis
bifonazole
terbinafine
latoconazole
Antifungal Agents
4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Dermatology

Cite this

Jarratt, M., Jones, T., Kempers, S., Rich, P., Morton, K., Nakamura, N., & Tavakkol, A. (2013). Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study. Cutis, 91(4), 203-210.

Luliconazole for the treatment of interdigital tinea pedis : A double-blind, vehicle-controlled study. / Jarratt, Michael; Jones, Terry; Kempers, Steven; Rich, Phoebe; Morton, Katy; Nakamura, Norifumi; Tavakkol, Amir.

In: Cutis, Vol. 91, No. 4, 22.08.2013, p. 203-210.

Research output: Contribution to journalArticle

Jarratt, M, Jones, T, Kempers, S, Rich, P, Morton, K, Nakamura, N & Tavakkol, A 2013, 'Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study', Cutis, vol. 91, no. 4, pp. 203-210.
Jarratt M, Jones T, Kempers S, Rich P, Morton K, Nakamura N et al. Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study. Cutis. 2013 Aug 22;91(4):203-210.
Jarratt, Michael ; Jones, Terry ; Kempers, Steven ; Rich, Phoebe ; Morton, Katy ; Nakamura, Norifumi ; Tavakkol, Amir. / Luliconazole for the treatment of interdigital tinea pedis : A double-blind, vehicle-controlled study. In: Cutis. 2013 ; Vol. 91, No. 4. pp. 203-210.
@article{4f4aa2265b6a4f458730f835b78a810c,
title = "Luliconazole for the treatment of interdigital tinea pedis: A double-blind, vehicle-controlled study",
abstract = "Tinea pedis (TP) typically is treated with topical antifungal agents. Luliconazole, a novel imidazole drug, is shown to be as or more effective in vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment durations with luliconazole cream 1{\%} were evaluated for treatment of TP. Participants with interdigital TP were randomized (N=147) and treated with either luliconazole or its vehicle for either 2 or 4 weeks. The primary efficacy end point was the proportion of participants achieving complete clearance 2 weeks following completion of treatment. In the 2-week active treatment group, complete clearance was achieved in 26.8{\%} (11/41) of participants versus 9.1{\%} (2/22) in the 2-week vehicle group at 2-weeks posttreatment. In the 4-week active treatment group, 45.7{\%} (16/35) achieved complete clearance versus 10.0{\%} (2/20) in the 4-week vehicle group at 2-weeks posttreatment. Twenty-three adverse events (AEs) were reported; most were mild (56.5{\%} [13/23]) to moderate (26.1{\%} [6/23]) in severity. All reported AEs were determined to be unrelated (78.3{\%} [18/23]) or unlikely related (21.7{\%} [5/23]) to the study medication. The results of this study indicate that luliconazole cream 1{\%} applied once daily for either 2 or 4 weeks is safe and effective for treatment of TP. More importantly, the antifungal effects of luliconazole persist for several weeks, resulting in increased rates of mycological cure.",
author = "Michael Jarratt and Terry Jones and Steven Kempers and Phoebe Rich and Katy Morton and Norifumi Nakamura and Amir Tavakkol",
year = "2013",
month = "8",
day = "22",
language = "English (US)",
volume = "91",
pages = "203--210",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "4",

}

TY - JOUR

T1 - Luliconazole for the treatment of interdigital tinea pedis

T2 - A double-blind, vehicle-controlled study

AU - Jarratt, Michael

AU - Jones, Terry

AU - Kempers, Steven

AU - Rich, Phoebe

AU - Morton, Katy

AU - Nakamura, Norifumi

AU - Tavakkol, Amir

PY - 2013/8/22

Y1 - 2013/8/22

N2 - Tinea pedis (TP) typically is treated with topical antifungal agents. Luliconazole, a novel imidazole drug, is shown to be as or more effective in vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment durations with luliconazole cream 1% were evaluated for treatment of TP. Participants with interdigital TP were randomized (N=147) and treated with either luliconazole or its vehicle for either 2 or 4 weeks. The primary efficacy end point was the proportion of participants achieving complete clearance 2 weeks following completion of treatment. In the 2-week active treatment group, complete clearance was achieved in 26.8% (11/41) of participants versus 9.1% (2/22) in the 2-week vehicle group at 2-weeks posttreatment. In the 4-week active treatment group, 45.7% (16/35) achieved complete clearance versus 10.0% (2/20) in the 4-week vehicle group at 2-weeks posttreatment. Twenty-three adverse events (AEs) were reported; most were mild (56.5% [13/23]) to moderate (26.1% [6/23]) in severity. All reported AEs were determined to be unrelated (78.3% [18/23]) or unlikely related (21.7% [5/23]) to the study medication. The results of this study indicate that luliconazole cream 1% applied once daily for either 2 or 4 weeks is safe and effective for treatment of TP. More importantly, the antifungal effects of luliconazole persist for several weeks, resulting in increased rates of mycological cure.

AB - Tinea pedis (TP) typically is treated with topical antifungal agents. Luliconazole, a novel imidazole drug, is shown to be as or more effective in vitro and in vivo than bifonazole, terbinafine, and lanoconazole. Two treatment durations with luliconazole cream 1% were evaluated for treatment of TP. Participants with interdigital TP were randomized (N=147) and treated with either luliconazole or its vehicle for either 2 or 4 weeks. The primary efficacy end point was the proportion of participants achieving complete clearance 2 weeks following completion of treatment. In the 2-week active treatment group, complete clearance was achieved in 26.8% (11/41) of participants versus 9.1% (2/22) in the 2-week vehicle group at 2-weeks posttreatment. In the 4-week active treatment group, 45.7% (16/35) achieved complete clearance versus 10.0% (2/20) in the 4-week vehicle group at 2-weeks posttreatment. Twenty-three adverse events (AEs) were reported; most were mild (56.5% [13/23]) to moderate (26.1% [6/23]) in severity. All reported AEs were determined to be unrelated (78.3% [18/23]) or unlikely related (21.7% [5/23]) to the study medication. The results of this study indicate that luliconazole cream 1% applied once daily for either 2 or 4 weeks is safe and effective for treatment of TP. More importantly, the antifungal effects of luliconazole persist for several weeks, resulting in increased rates of mycological cure.

UR - http://www.scopus.com/inward/record.url?scp=84879954054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879954054&partnerID=8YFLogxK

M3 - Article

C2 - 23763082

AN - SCOPUS:84879954054

VL - 91

SP - 203

EP - 210

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 4

ER -